DIAG723
Diagonal Therapeutics is running a clinical trial of DIAG723 in people with hereditary hemorrhagic telangiectasia (HHT).
Sites are currently open in Australia and New Zealand, with further sites to be announced.
If you would like the study team to know you are interested, Cure HHT collects expressions of interest through a short form. Completing it does not commit you to anything.